Aurobindo receives FDA nod for generic Rozerem
Ramelteon tablets are indicated as a treatment for insomnia characterized by difficulty with sleep onset.
Aurobindo has received the Food and Drug Administration’s blessing for Ramelteon tablets, which are a generic of Takeda’s Rozerem.
Ramelteon tablets are indicated as a treatment of insomnia characterized by difficulty with sleep onset.
[Read more: Aurobindo obtains FDA OK for 2 generics]
Ramelteon tablets have a market value of roughly $20.6 million for the 12 months ending May 2023, per IQVIA.